APO Research
Talk to an analyst

APO RESEARCH · REPORT

Erlotinib Generics

Compare research editions
View pricing & licenses

Selected research

Industry Research

Erlotinib Generics Industry Research Report 2026

27 December 2025129 pages

Choose your research edition.

Industry ResearchErlotinib Generics Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Erlotinib Generics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Erlotinib Generics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Erlotinib Generics Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Erlotinib Generics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Erlotinib Generics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Erlotinib Generics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Erlotinib Generics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Erlotinib Generics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Erlotinib Generics include Thery Pharm, Shenzhen Salubris Pharmaceuticals, Acebright Pharma, Shandong Loncom Pharma, Jilin Aodong Taonan Pharmaceutical, Hansoh Pharma, Teva, Taj Pharma and Sun Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Erlotinib Generics market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Erlotinib Generics Market by Company

Thery Pharm

Shenzhen Salubris Pharmaceuticals

Acebright Pharma

Shandong Loncom Pharma

Jilin Aodong Taonan Pharmaceutical

Hansoh Pharma

Teva

Taj Pharma

Sun Pharmaceutical

Natco Pharma

Mylan

Glenmark Pharmaceuticals

Cipla

Aristopharma

Erlotinib Generics Segment by Type

25mg per Tablet

150mg per Tablet

100mg per Tablet

Erlotinib Generics Segment by Application

Retail Pharmacies

Hospital and Clinic

Other

Erlotinib Generics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Erlotinib Generics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Erlotinib Generics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Erlotinib Generics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Erlotinib Generics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Erlotinib Generics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Erlotinib Generics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Erlotinib Generics Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Erlotinib Generics Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Erlotinib Generics Sales Market Share by Manufacturers (2021-2026) Table 8. Global Erlotinib Generics Revenue of Manufacturers (2021-2026) Table 9. Global Erlotinib Generics Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Erlotinib Generics Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Erlotinib Generics Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Erlotinib Generics, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Erlotinib Generics, Product Type & Application Table 14. Global Erlotinib Generics Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Erlotinib Generics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Thery Pharm Company Information Table 19. Thery Pharm Business Overview Table 20. Thery Pharm Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Thery Pharm Erlotinib Generics Product Portfolio Table 22. Thery Pharm Recent Developments Table 23. Shenzhen Salubris Pharmaceuticals Company Information Table 24. Shenzhen Salubris Pharmaceuticals Business Overview Table 25. Shenzhen Salubris Pharmaceuticals Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Shenzhen Salubris Pharmaceuticals Erlotinib Generics Product Portfolio Table 27. Shenzhen Salubris Pharmaceuticals Recent Developments Table 28. Acebright Pharma Company Information Table 29. Acebright Pharma Business Overview Table 30. Acebright Pharma Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Acebright Pharma Erlotinib Generics Product Portfolio Table 32. Acebright Pharma Recent Developments Table 33. Shandong Loncom Pharma Company Information Table 34. Shandong Loncom Pharma Business Overview Table 35. Shandong Loncom Pharma Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Shandong Loncom Pharma Erlotinib Generics Product Portfolio Table 37. Shandong Loncom Pharma Recent Developments Table 38. Jilin Aodong Taonan Pharmaceutical Company Information Table 39. Jilin Aodong Taonan Pharmaceutical Business Overview Table 40. Jilin Aodong Taonan Pharmaceutical Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Jilin Aodong Taonan Pharmaceutical Erlotinib Generics Product Portfolio Table 42. Jilin Aodong Taonan Pharmaceutical Recent Developments Table 43. Hansoh Pharma Company Information Table 44. Hansoh Pharma Business Overview Table 45. Hansoh Pharma Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Hansoh Pharma Erlotinib Generics Product Portfolio Table 47. Hansoh Pharma Recent Developments Table 48. Teva Company Information Table 49. Teva Business Overview Table 50. Teva Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Teva Erlotinib Generics Product Portfolio Table 52. Teva Recent Developments Table 53. Taj Pharma Company Information Table 54. Taj Pharma Business Overview Table 55. Taj Pharma Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Taj Pharma Erlotinib Generics Product Portfolio Table 57. Taj Pharma Recent Developments Table 58. Sun Pharmaceutical Company Information Table 59. Sun Pharmaceutical Business Overview Table 60. Sun Pharmaceutical Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Sun Pharmaceutical Erlotinib Generics Product Portfolio Table 62. Sun Pharmaceutical Recent Developments Table 63. Natco Pharma Company Information Table 64. Natco Pharma Business Overview Table 65. Natco Pharma Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Natco Pharma Erlotinib Generics Product Portfolio Table 67. Natco Pharma Recent Developments Table 68. Mylan Company Information Table 69. Mylan Business Overview Table 70. Mylan Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Mylan Erlotinib Generics Product Portfolio Table 72. Mylan Recent Developments Table 73. Glenmark Pharmaceuticals Company Information Table 74. Glenmark Pharmaceuticals Business Overview Table 75. Glenmark Pharmaceuticals Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Glenmark Pharmaceuticals Erlotinib Generics Product Portfolio Table 77. Glenmark Pharmaceuticals Recent Developments Table 78. Cipla Company Information Table 79. Cipla Business Overview Table 80. Cipla Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Cipla Erlotinib Generics Product Portfolio Table 82. Cipla Recent Developments Table 83. Aristopharma Company Information Table 84. Aristopharma Business Overview Table 85. Aristopharma Erlotinib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Aristopharma Erlotinib Generics Product Portfolio Table 87. Aristopharma Recent Developments Table 88. Global Erlotinib Generics Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global Erlotinib Generics Sales by Region (2021-2026) & (K Units) Table 90. Global Erlotinib Generics Sales Market Share by Region (2021-2026) Table 91. Global Erlotinib Generics Sales by Region (2027-2032) & (K Units) Table 92. Global Erlotinib Generics Sales Market Share by Region (2027-2032) Table 93. Global Erlotinib Generics Revenue by Region (2021-2026) & (US$ Million) Table 94. Global Erlotinib Generics Revenue Market Share by Region (2021-2026) Table 95. Global Erlotinib Generics Revenue by Region (2027-2032) & (US$ Million) Table 96. Global Erlotinib Generics Revenue Market Share by Region (2027-2032) Table 97. North America Erlotinib Generics Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America Erlotinib Generics Sales by Country (2021-2026) & (K Units) Table 99. North America Erlotinib Generics Sales by Country (2027-2032) & (K Units) Table 100. North America Erlotinib Generics Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Erlotinib Generics Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe Erlotinib Generics Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe Erlotinib Generics Sales by Country (2021-2026) & (K Units) Table 104. Europe Erlotinib Generics Sales by Country (2027-2032) & (K Units) Table 105. Europe Erlotinib Generics Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Erlotinib Generics Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific Erlotinib Generics Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific Erlotinib Generics Sales by Country (2021-2026) & (K Units) Table 109. Asia Pacific Erlotinib Generics Sales by Country (2027-2032) & (K Units) Table 110. Asia Pacific Erlotinib Generics Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific Erlotinib Generics Revenue by Country (2027-2032) & (US$ Million) Table 112. South America Erlotinib Generics Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America Erlotinib Generics Sales by Country (2021-2026) & (K Units) Table 114. South America Erlotinib Generics Sales by Country (2027-2032) & (K Units) Table 115. South America Erlotinib Generics Revenue by Country (2021-2026) & (US$ Million) Table 116. South America Erlotinib Generics Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa Erlotinib Generics Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa Erlotinib Generics Sales by Country (2021-2026) & (K Units) Table 119. Middle East and Africa Erlotinib Generics Sales by Country (2027-2032) & (K Units) Table 120. Middle East and Africa Erlotinib Generics Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa Erlotinib Generics Revenue by Country (2027-2032) & (US$ Million) Table 122. Global Erlotinib Generics Sales by Type (2021-2026) & (K Units) Table 123. Global Erlotinib Generics Sales by Type (2027-2032) & (K Units) Table 124. Global Erlotinib Generics Sales Market Share by Type (2021-2026) Table 125. Global Erlotinib Generics Sales Market Share by Type (2027-2032) Table 126. Global Erlotinib Generics Revenue by Type (2021-2026) & (US$ Million) Table 127. Global Erlotinib Generics Revenue by Type (2027-2032) & (US$ Million) Table 128. Global Erlotinib Generics Revenue Market Share by Type (2021-2026) Table 129. Global Erlotinib Generics Revenue Market Share by Type (2027-2032) Table 130. Global Erlotinib Generics Price by Type (2021-2026) & (US$/Unit) Table 131. Global Erlotinib Generics Price by Type (2027-2032) & (US$/Unit) Table 132. Global Erlotinib Generics Sales by Application (2021-2026) & (K Units) Table 133. Global Erlotinib Generics Sales by Application (2027-2032) & (K Units) Table 134. Global Erlotinib Generics Sales Market Share by Application (2021-2026) Table 135. Global Erlotinib Generics Sales Market Share by Application (2027-2032) Table 136. Global Erlotinib Generics Revenue by Application (2021-2026) & (US$ Million) Table 137. Global Erlotinib Generics Revenue by Application (2027-2032) & (US$ Million) Table 138. Global Erlotinib Generics Revenue Market Share by Application (2021-2026) Table 139. Global Erlotinib Generics Revenue Market Share by Application (2027-2032) Table 140. Global Erlotinib Generics Price by Application (2021-2026) & (US$/Unit) Table 141. Global Erlotinib Generics Price by Application (2027-2032) & (US$/Unit) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Erlotinib Generics Distributors List Table 145. Erlotinib Generics Customers List Table 146. Erlotinib Generics Industry Trends Table 147. Erlotinib Generics Industry Drivers Table 148. Erlotinib Generics Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Erlotinib Generics Product Image Figure 5. Global Erlotinib Generics Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Erlotinib Generics Market Size (2021-2032) & (US$ Million) Figure 7. Global Erlotinib Generics Sales (2021-2032) & (K Units) Figure 8. Global Erlotinib Generics Average Price (US$/Unit) & (2021-2032) Figure 9. 25mg per Tablet Product Image Figure 10. 150mg per Tablet Product Image Figure 11. 100mg per Tablet Product Image Figure 12. Retail Pharmacies Product Image Figure 13. Hospital and Clinic Product Image Figure 14. Other Product Image Figure 15. Global Erlotinib Generics Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Erlotinib Generics, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Erlotinib Generics Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Erlotinib Generics Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Erlotinib Generics Sales by Region in 2025 Figure 21. Global Erlotinib Generics Revenue by Region in 2025 Figure 22. North America Erlotinib Generics Market Size by Country in 2025 Figure 23. North America Erlotinib Generics Sales Market Share by Country (2021-2032) Figure 24. North America Erlotinib Generics Revenue Market Share by Country (2021-2032) Figure 25. United States Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Erlotinib Generics Market Size by Country in 2025 Figure 29. Europe Erlotinib Generics Sales Market Share by Country (2021-2032) Figure 30. Europe Erlotinib Generics Revenue Market Share by Country (2021-2032) Figure 31. Germany Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Erlotinib Generics Market Size by Country in 2025 Figure 42. Asia Pacific Erlotinib Generics Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Erlotinib Generics Revenue Market Share by Country (2021-2032) Figure 44. China Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Erlotinib Generics Market Size by Country in 2025 Figure 53. South America Erlotinib Generics Sales Market Share by Country (2021-2032) Figure 54. South America Erlotinib Generics Revenue Market Share by Country (2021-2032) Figure 55. Brazil Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Colombia Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Erlotinib Generics Market Size by Country in 2025 Figure 60. Middle East and Africa Erlotinib Generics Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Erlotinib Generics Revenue Market Share by Country (2021-2032) Figure 62. Egypt Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Erlotinib Generics Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Erlotinib Generics Sales Market Share by Type (2021-2032) Figure 68. Global Erlotinib Generics Revenue Market Share by Type (2021-2032) Figure 69. Global Erlotinib Generics Price (US$/Unit) by Type (2021-2032) Figure 70. Global Erlotinib Generics Sales Market Share by Application (2021-2032) Figure 71. Global Erlotinib Generics Revenue Market Share by Application (2021-2032) Figure 72. Global Erlotinib Generics Price (US$/Unit) by Application (2021-2032) Figure 73. Erlotinib Generics Value Chain Figure 74. Erlotinib Generics Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Erlotinib Generics Industry Opportunities and Challenges

Scope & coverage.

Types
  • 25mg per Tablet
  • 150mg per Tablet
  • 100mg per Tablet
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Other
Companies covered
  • Thery Pharm
  • Shenzhen Salubris Pharmaceuticals
  • Acebright Pharma
  • Shandong Loncom Pharma
  • Jilin Aodong Taonan Pharmaceutical
  • Hansoh Pharma
  • Teva
  • Taj Pharma
  • Sun Pharmaceutical
  • Natco Pharma
  • Mylan
  • Glenmark Pharmaceuticals
  • Cipla
  • Aristopharma

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Erlotinib Generics Market Size (2021-2032)
  4. 2.2.2 Global Erlotinib Generics Sales (2021-2032)
  5. 2.2.3 Global Erlotinib Generics Market Average Price (2021-2032)
  6. 2.3 Erlotinib Generics by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 25mg per Tablet
  9. 2.3.3 150mg per Tablet
  10. 2.3.4 100mg per Tablet
  11. 2.4 Erlotinib Generics by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Retail Pharmacies
  14. 2.4.3 Hospital and Clinic
  15. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Erlotinib Generics Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Erlotinib Generics Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Erlotinib Generics Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Erlotinib Generics Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Erlotinib Generics Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Erlotinib Generics, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Erlotinib Generics, Product Type & Application
  8. 3.8 Global Manufacturers of Erlotinib Generics, Established Date
  9. 3.9 Global Erlotinib Generics Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Thery Pharm
  2. 4.1.1 Thery Pharm Company Information
  3. 4.1.2 Thery Pharm Business Overview
  4. 4.1.3 Thery Pharm Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Thery Pharm Erlotinib Generics Product Portfolio
  6. 4.1.5 Thery Pharm Recent Developments
  7. 4.2 Shenzhen Salubris Pharmaceuticals
  8. 4.2.1 Shenzhen Salubris Pharmaceuticals Company Information
  9. 4.2.2 Shenzhen Salubris Pharmaceuticals Business Overview
  10. 4.2.3 Shenzhen Salubris Pharmaceuticals Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Shenzhen Salubris Pharmaceuticals Erlotinib Generics Product Portfolio
  12. 4.2.5 Shenzhen Salubris Pharmaceuticals Recent Developments
  13. 4.3 Acebright Pharma
  14. 4.3.1 Acebright Pharma Company Information
  15. 4.3.2 Acebright Pharma Business Overview
  16. 4.3.3 Acebright Pharma Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Acebright Pharma Erlotinib Generics Product Portfolio
  18. 4.3.5 Acebright Pharma Recent Developments
  19. 4.4 Shandong Loncom Pharma
  20. 4.4.1 Shandong Loncom Pharma Company Information
  21. 4.4.2 Shandong Loncom Pharma Business Overview
  22. 4.4.3 Shandong Loncom Pharma Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Shandong Loncom Pharma Erlotinib Generics Product Portfolio
  24. 4.4.5 Shandong Loncom Pharma Recent Developments
  25. 4.5 Jilin Aodong Taonan Pharmaceutical
  26. 4.5.1 Jilin Aodong Taonan Pharmaceutical Company Information
  27. 4.5.2 Jilin Aodong Taonan Pharmaceutical Business Overview
  28. 4.5.3 Jilin Aodong Taonan Pharmaceutical Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Jilin Aodong Taonan Pharmaceutical Erlotinib Generics Product Portfolio
  30. 4.5.5 Jilin Aodong Taonan Pharmaceutical Recent Developments
  31. 4.6 Hansoh Pharma
  32. 4.6.1 Hansoh Pharma Company Information
  33. 4.6.2 Hansoh Pharma Business Overview
  34. 4.6.3 Hansoh Pharma Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Hansoh Pharma Erlotinib Generics Product Portfolio
  36. 4.6.5 Hansoh Pharma Recent Developments
  37. 4.7 Teva
  38. 4.7.1 Teva Company Information
  39. 4.7.2 Teva Business Overview
  40. 4.7.3 Teva Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Teva Erlotinib Generics Product Portfolio
  42. 4.7.5 Teva Recent Developments
  43. 4.8 Taj Pharma
  44. 4.8.1 Taj Pharma Company Information
  45. 4.8.2 Taj Pharma Business Overview
  46. 4.8.3 Taj Pharma Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Taj Pharma Erlotinib Generics Product Portfolio
  48. 4.8.5 Taj Pharma Recent Developments
  49. 4.9 Sun Pharmaceutical
  50. 4.9.1 Sun Pharmaceutical Company Information
  51. 4.9.2 Sun Pharmaceutical Business Overview
  52. 4.9.3 Sun Pharmaceutical Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Sun Pharmaceutical Erlotinib Generics Product Portfolio
  54. 4.9.5 Sun Pharmaceutical Recent Developments
  55. 4.10 Natco Pharma
  56. 4.10.1 Natco Pharma Company Information
  57. 4.10.2 Natco Pharma Business Overview
  58. 4.10.3 Natco Pharma Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Natco Pharma Erlotinib Generics Product Portfolio
  60. 4.10.5 Natco Pharma Recent Developments
  61. 4.11 Mylan
  62. 4.11.1 Mylan Company Information
  63. 4.11.2 Mylan Business Overview
  64. 4.11.3 Mylan Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Mylan Erlotinib Generics Product Portfolio
  66. 4.11.5 Mylan Recent Developments
  67. 4.12 Glenmark Pharmaceuticals
  68. 4.12.1 Glenmark Pharmaceuticals Company Information
  69. 4.12.2 Glenmark Pharmaceuticals Business Overview
  70. 4.12.3 Glenmark Pharmaceuticals Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Glenmark Pharmaceuticals Erlotinib Generics Product Portfolio
  72. 4.12.5 Glenmark Pharmaceuticals Recent Developments
  73. 4.13 Cipla
  74. 4.13.1 Cipla Company Information
  75. 4.13.2 Cipla Business Overview
  76. 4.13.3 Cipla Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Cipla Erlotinib Generics Product Portfolio
  78. 4.13.5 Cipla Recent Developments
  79. 4.14 Aristopharma
  80. 4.14.1 Aristopharma Company Information
  81. 4.14.2 Aristopharma Business Overview
  82. 4.14.3 Aristopharma Erlotinib Generics Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Aristopharma Erlotinib Generics Product Portfolio
  84. 4.14.5 Aristopharma Recent Developments
5 Global Erlotinib Generics Market Scenario by Region
  1. 5.1 Global Erlotinib Generics Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Erlotinib Generics Sales by Region: 2021-2032
  3. 5.2.1 Global Erlotinib Generics Sales by Region: 2021-2026
  4. 5.2.2 Global Erlotinib Generics Sales by Region: 2027-2032
  5. 5.3 Global Erlotinib Generics Revenue by Region: 2021-2032
  6. 5.3.1 Global Erlotinib Generics Revenue by Region: 2021-2026
  7. 5.3.2 Global Erlotinib Generics Revenue by Region: 2027-2032
  8. 5.4 North America Erlotinib Generics Market Facts & Figures by Country
  9. 5.4.1 North America Erlotinib Generics Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Erlotinib Generics Sales by Country (2021-2032)
  11. 5.4.3 North America Erlotinib Generics Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Erlotinib Generics Market Facts & Figures by Country
  16. 5.5.1 Europe Erlotinib Generics Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Erlotinib Generics Sales by Country (2021-2032)
  18. 5.5.3 Europe Erlotinib Generics Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Erlotinib Generics Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Erlotinib Generics Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Erlotinib Generics Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Erlotinib Generics Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Erlotinib Generics Market Facts & Figures by Country
  41. 5.7.1 South America Erlotinib Generics Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Erlotinib Generics Sales by Country (2021-2032)
  43. 5.7.3 South America Erlotinib Generics Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Erlotinib Generics Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Erlotinib Generics Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Erlotinib Generics Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Erlotinib Generics Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Erlotinib Generics Sales by Type (2021-2032)
  2. 6.1.1 Global Erlotinib Generics Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Erlotinib Generics Sales Market Share by Type (2021-2032)
  4. 6.2 Global Erlotinib Generics Revenue by Type (2021-2032)
  5. 6.2.1 Global Erlotinib Generics Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Erlotinib Generics Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Erlotinib Generics Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Erlotinib Generics Sales by Application (2021-2032)
  2. 7.1.1 Global Erlotinib Generics Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Erlotinib Generics Sales Market Share by Application (2021-2032)
  4. 7.2 Global Erlotinib Generics Revenue by Application (2021-2032)
  5. 7.2.1 Global Erlotinib Generics Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Erlotinib Generics Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Erlotinib Generics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Erlotinib Generics Value Chain Analysis
  2. 8.1.1 Erlotinib Generics Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Erlotinib Generics Production Mode & Process
  5. 8.2 Erlotinib Generics Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Erlotinib Generics Distributors
  8. 8.2.3 Erlotinib Generics Customers
9 Global Erlotinib Generics Analyzing Market Dynamics
  1. 9.1 Erlotinib Generics Industry Trends
  2. 9.2 Erlotinib Generics Industry Drivers
  3. 9.3 Erlotinib Generics Industry Opportunities and Challenges
  4. 9.4 Erlotinib Generics Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst